Management of betablocked patients after sustained virological response in hepatitis C cirrhosis

Table 1 Patients characteristics

	n = 33
Age (yr), median (P25-P75)	64 (59-73)
Males, n (%)	18 (54.5)
BMI > 25 kg/m2, n (%)	26 (78.8)
ALT (UI/L), median (P25-P75)	21 (18-26)
Platelets (× 103/μL), median (P25-P75)	77 (58-100)
Total bilirubin (mg/dL), median (P25-P75)	1.1 (0.8-1.6)
Albumin (g/dL), median (P25-P75)	3.9 (3.8-4.1)
Baseline Child-Pugh A/B/C, n (%)	25 (75.8)/8 (24.2)/0
HVPG Child-Pugh A/B/C, n (%)	30 (90.9)/3 (9.1)/0
Baseline MELD score, median (P25-P75)	10 (9-11)
HVPG MELD score, median (P25-P75)	9 (8-12)
Baseline TE (kPa), median (P25-P75)	24.8 (17.3-34.3)
HVPG TE (kPa), median (P25-P75)	21.7 (16.6-26.8)
Baseline ascites, n (%)	12 (36.4)
HVPG ascites, n (%)	3 (9.1)
Propranolol/Carvedilol, n (%)	14 (46.7)/16 (53.3)
Primary prophylaxis indication, n (%)	29 (88)
Large oesophageal varices	26 (79)
Small oesophageal varices + Child-Pugh B	3 (9)
Secondary prophylaxis, n (%)	4 (12)

Baseline refers to data before direct-acting antivirals treatment. Hepatic venous pressure gradient (HVPG) refers to results on the day of the haemodynamic study. Baseline ascites or under diuretic treatment for previous ascites. The most recent ligations had been performed at least 10 mo before HVPG. BMI: Body mass index; ALT: Alanine-aminotransferase; HVPG: Hepatic venous pressure gradient; MELD: Model for End-Stage Liver Disease; TE: Transient elastography.